Τόμος 24 (2010) – Τεύχος 2 – Άρθρο 37 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Διεθνής Έκδοση – Volume 24 (2010) – Issue 2 – Article 37 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-International Edition

Laboratory of Pharmacology, Department of Pharmaceutical Sciences, Aristotle University of Thessaloniki (A.U.TH.), GR-54124, Thessaloniki, GREECE

pharmakonpress[at]pharmakonpress[.]gr

2. Melo J.V., Chuah C.: Resistance to imatinib mesylate in chronic myeloid leukaemia. Cancer Lett. 249: 121 (2007)

3. Kerkela R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., Walters B., Shevtsov S., Pesant S.,  Clubb F.J., Rosenzweig A., Salomon R.N., Van Etten R.A., Alroy J., Durand J.B., Force T.: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12: 908 (2006)

4. Will Y., Dykens J.A., Nadanaciva S., Hirakawa B., Jamieson J., Marroquin L.D., Hynes J., Patyna S., Jessen B.A.: Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells: Toxicol. Sci. 106: 153 (2008)

5. Papadopoulou L.C., Sue C.M., Davidson M.M., Tanji K., Nishino I., Sadlock J.E., Krishna S., Walker W., Selby J., Glerum D.M., Coster R.V., Lyon G., Scalais E., Lebel R., Kaplan P., Shanske S., De Vivo D.C., Bonilla E., Hirano M., DiMauro S., Schon E.A.: Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene, Nat. Genet. 23: 333 (1999)

6. Tsiftsoglou A.S., Tsamadou A.I., Papadopoulou L.C.: Heme as key regulator of major mammalian cellular functions: molecular, cellular, and pharmacological aspects. Pharmacol. Ther. 111: 327 (2006)

7. Bonovolias I.D., Manley P.W., Tsiftsoglou A.S.: Hemin confers resistance to Imatinib (Gleevec)-induced cell death but enhances Nilotinib (AMN107) cytotoxicity in human K-562 CML leukemia cells. Blood 108: 4769 (2006)

8. Mayerhofer M., Florian S., Krauth M.T., Aichberger K.J., Bilban M., Marculescu R., Printz D., Fritsch G., Wagner O., Selzer E., Sperr W.R., Valent P., Sillaber C.: Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. Cancer Res. 64: 3148 (2004)

9. Mayerhofer M., Gleixner K.V., Mayerhofer J., Hoermann G., Jaeger E., Aichberger K.J., Ott R.G., Greish K., Nakamura H., Derdak S., Samorapoompichit P., Pickl W.F., Sexl V., Esterbauer H., Schwarzinger I., Sillaber C., Maeda H., Valent P.: Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood 111: 2200 (2008).

10. Bonovolias, I. D., and Tsiftsoglou, A. S., Hemin counteracts the repression of Bcl-2 and NrF2 genes and the cell killing induced by imatinib in human Bcr-Abl(+) CML cells, Oncol Res, 17, 535 (2009)

11. Foltopoulou P.F., Tsiftsoglou A.S., Bonovolias I.D., Ingendoh A.T., Papadopoulou L.C.: Intracellular delivery of full length recombinant human mitochondrial L-Sco2 protein into the mitochondria of permanent cell lines and SCO2 deficient patient’s primary cells. Biochim. Biophys. Acta: (2010)

12. Lozzio B.B., Lozzio C.B.: Properties and usefulness of the original K-562 human myelogenous leukemia cell line. Leuk Res. 3: 363 (1979)

13. Chomczynski P., Sacchi N.: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal. Biochem. 162: 156 (1987)

pharmakonpress[at]pharmakonpress[.]gr

pharmakonpress[at]pharmakonpress[.]gr